FGF23 and hypophosphatemic rickets: Moreover, it is a valuable diagnostic tool in primary disorders associated with FGF23 overproduction, such as hypophosphatemic rickets or tumor-induced osteomalacia, where it also serves as a therapeutic target following the development of an anti-FGF23 antibody (Burosumab) [18].